The Diagnostic Performance of Afirma Gene Expression Classifier for the Indeterminate Thyroid Nodules: A Meta-Analysis

Table 5

Summary of final surgical pathology at resection of all surgical nodules (N=960).

	Pathological Diagnoses after Surgery
	Benign		Malignant
	Diagnosis	No.(%)	Diagnosis	No.(%)
Final Surgical Pathology	Follicular adenoma	139(31.2%)	cvPTC	228(44.3%)
	Benign follicular nodule	71(16.0%)	FvPTC	197(38.3%)
	Adenomatoid nodule	58(13.0%)	PTC, HC
	Nodular hyperplasia	56(12.6%)	features/variant	2(0.4%)
	HCA	49(11.0%)	NIFPTC	15(2.9%)
	Oncocytic follicular		FTC	39(7.6%)
	adenoma	22(4.9%)	HCC	24(4.7%)
	Chronic lymphocytic		MTC	6(1.2%)
	thyroiditis	9(2.0%)	Malignant lymphoma	2(0.4%)
	MNG	5(1.1%)	Others	2(0.4%)
	Graves’ Disease	2(0.4%)
	Chronic inflammation	1(0.2%)
	Others	33(7.4%)
Total		445(100%)		515(100%)

PTC, papillary thyroid carcinoma; FTC: follicular thyroid carcinoma; MTC: medullary thyroid cancer; AN, adenomatous/hyperplasic nodule; cvPTC, classic variant of papillary thyroid carcinoma; fvPTC, follicular variant of papillary thyroid carcinoma; NIFPTC, noninvasive follicular neoplasm with papillary-like nuclear features; PTC, HC feature: papillary thyroid carcinoma with Hürthle cell; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma.